21 results about "Disease pathogenesis" patented technology

The invention discloses a Parkinson's disease animal model, a construction method and application, and relates to the field of animal genetic engineering and disease model construction. According to the model, seven mutation sites related to the human familial Parkinson's disease are introduced behind an initiation codon of a fourth exon of an endogenous SNCA gene, and the mutation sites are A18T, A29S, A30P, E46K, H50Q, G51D and A53T and have genotypes related to the human familial Parkinson's disease. The pig model shows nigra dopaminergic neuron reduction and cortical neuron reduction in the newborn period, and the core pathological process of the human Parkinson's disease can be systematically reproduced. The model can be widely applied to Parkinson's disease pathogenesis research, drug screening and cell therapy effect evaluation, and has important scientific research and preclinical application values.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, Methods and compositions for determining cancer and subtypes, including breast cancer are described and specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at identifying candidates for responsiveness and overcoming resistance mechanisms.

Described herein is a microphysiological system for models of disease. Specifically, induced pluripotent stem cells (iPSCs) and iPSC-derived cells, including those obtained from disease patients, are seeded onto microfluidic “chip” devices to study cellular development and disease pathogenesis. Herein, neurodegenerative disease modeling, including Parkinson's Disease (PD) is shown to reproduce key PD pathology in a vascularized human model that contains neurons relating to PD pathology. Such compositions and methods are used for research for PD biomarkers, patient screening for PD risk assessment, and therapeutic discovery and testing. A panel of biomarkers are generated through analysis of living PD-chips by neural activity, whole transcriptomic, proteomic, and metabolomic analysis, and functional enzyme tests of media and tissue. Introducing therapeutics through a vasculature channel, coupled with blood brain barrier penetration studies can be assessed for efficacy in the human neural cells present in the PD-Chip.

Methods and compositions for treating and preventing cell ballooning and other diseases or medical conditions are provided. The diseases or medical conditions are characterized by cell degeneration or cell death as a part of the disease pathogenesis. Cell ballooning is a condition associated with storage of excess fat in the liver. nutritional or biochemical imbalance, damage to mitochondria, ATP depletion, or virus infection. A mitochondrially targeted antioxidant compound is administered to a subject in need thereof, whereby excess fat is metabolized.

Described herein are gene features that provide prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, including immune checkpoint regulators such as Programmed Death Ligand 1 (PDL-1). Using the methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers indicate disease pathogenesis, which provides opportunities for selection of treatments, including treatment regimens intended to overcome tolerance mechanisms.

Described herein are gene features for providing prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, methods and compositions for determining cancer and subtypes, including breast cancer, and provide specific and sensitive detection of biomarkers of interest. Such biomarkers indicate disease pathogenesis, which provides opportunities to select treatment, including treatment regimens intended to identify responsive candidates and overcome resistance mechanisms.

Disclosed herein are lipid nanoparticles and compositions thereof. Exemplary nanoparticle compositions include an ionizable lipid, a phospholipid, a PEG-lipid, and cholesterol modified with a hydroxyl group near the D-sterol ring. The disclosed nanoparticle compositions can more preferentially target liver Kupffer cells and endothelial cells than hepatocytes that should be beneficial in the treatment of liver diseases in which functional Kupffer cells and endothelial cells are involved in disease pathogenesis.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, including immune checkpoint regulators such as programmed death ligand 1 (PDL-1). Using methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at overcoming resistance mechanisms.

Described herein is a microphysiological system for models of disease. Specifically, induced pluripotent stem cells (iPSCs) and iPSC-derived cells, including those obtained from disease patients, are seeded onto microfluidic “chip” devices to study cellular development and disease pathogenesis. Herein, neurodegenerative disease modeling, including Parkinson's Disease (PD) is shown to reproduce key PD pathology in a vascularized human model that contains neurons relating to PD pathology. Such compositions and methods are used for research for PD biomarkers, patient screening for PD risk assessment, and therapeutic discovery and testing. A panel of biomarkers are generated through analysis of living PD-chips by neural activity, whole transcriptomic, proteomic, and metabolomic analysis, and functional enzyme tests of media and tissue. Introducing therapeutics through a vasculature channel, coupled with blood brain barrier penetration studies can be assessed for efficacy in the human neural cells present in the PD-Chip.

The invention discloses a screening method and application of an Asian human NMOSD high-pathogenicity antibody, and belongs to the technical field of autoimmune disease diagnosis and treatment. The screening method comprises the following steps: screening an Asian human NMOSD patient with poor glucocorticoid treatment prognosis, extracting serum AQP4-IgG, carrying out specific capture through M23 type AQP4 transfection cells, combining with primary astrocyte C3 inducibility verification, and screening to obtain the high-pathogenicity antibody. The antibody can mediate construction of a glucocorticoid treatment resistant NMOSD animal model, and is applied to disease pathogenic mechanism research and targeted drug screening. The antibody is screened on the basis of clinical prognosis phenotype and functional characteristics, sequence identification is not needed, the technical blank of Asian human NMOSD high-pathogenicity antibody screening is filled, and the application value is remarkable.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, Methods and compositions for determining cancer and subtypes, including breast cancer are described and specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at identifying candidates for responsiveness and overcoming resistance mechanisms.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, Methods and compositions for determining cancer and subtypes, including breast cancer are described and specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at identifying candidates for responsiveness and overcoming resistance mechanisms.

The invention provides a free-moving mouse stomach nerve optical genetic manipulation and stomach movement synchronous recording system. The system comprises an optical genetic nerve manipulation module, a stomach movement detection module, a wireless energy supply and control module, a time synchronization module and a data acquisition and fusion module. A miniature LED light source, a bridge strain gauge sensor and a wireless energy receiving coil which are implanted in vivo are matched with an in-vitro wireless energy supply, time synchronization and data acquisition assembly, so that optical genetic activation / inhibition of gastric autonomic nerves and high-resolution capture of gastric movement signals are realized, and time alignment of the gastric autonomic nerves and the gastric movement signals is realized by outputting TTL (Transistor-Transistor Logic) pulses by virtue of a micro-control unit; according to the system, the mouse does not need to be fixed or anesthetized, the implanted component is excellent in biocompatibility, long-term continuous recording can be achieved, time synchronization is accurate, and key technical support is provided for analyzing a stomach autonomic nerve innervation mechanism, exploring the relation between stomach autonomic nerve abnormity and stomach dyskinesia, studying gastrointestinal tract disease pathogenesis and the like.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The present invention provides a renal tubular organoid culture medium and its application, as well as a method for culturing renal tubular organoids. The renal tubular organoid culture medium of the present invention has a good supporting and promoting effect on the growth of renal tubular organoids. Typical renal tubular organoids can be obtained in about 7 days, and the consistency and heterogeneity of patient-derived tissue are well preserved in vitro, laying the foundation for further research and application of renal tubules. The culturing method of the renal tubular organoids of the present invention, which is cultured using the renal tubular organoid culture medium of the present invention, can effectively simulate renal tubular tissue and provide a powerful platform for the study of the pathogenesis and pathogenic factors of renal tubular-related diseases and the study of drug toxicity of normal renal tubular tissue. The culturing method of the present invention has simple and clear steps, and the operator has little influence on the culture results, which improves the consistency of the culture results and provides convenient conditions for subsequent large-scale culture.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The invention relates to the technical field of cell biology and biological medicine, in particular to a method for establishing an osteoclast model based on blue light irradiation combined with RANKL and application of the method. ChR2 genes are transfected into RAW264.7 cells through lentivirus, C-RAW264.7 cells of stable expression ChR2 protein are obtained, the C-RAW264.7 cells are induced to be differentiated into osteoclasts in combination with blue light irradiation and RANKL, and an obtained osteoclast model verifies that the number of the osteoclasts is large, differentiation is stable, and the osteoclast symbolic genes and protein can be expressed. Compared with the prior art, the osteoclast model disclosed by the invention is an osteoclast model capable of efficiently inducing and differentiating osteoclasts at low cost, and is expected to be applied to research on disease pathogenesis of osteoporosis, in particular to application research on screening medicines for regulating the concentration of Ca < 2 + > in the osteoclasts.

Methods for treating neurological and other disorders, including autoimmune disorders are described. Also described is a method of treating a disorder in which Toll-like Receptor 2 (TLR2) activation by binding to myeloid differentiation primary response 88 (MyD88) plays a role in disease pathogenesis. Further a method is described that includes the administration of a composition, including a peptide sequence, that inhibits the activation of TLR2 by MyD88.

Described herein are gene features for providing prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, methods and compositions for determining cancer and subtypes, including breast cancer, and provide specific and sensitive detection of biomarkers of interest. Such biomarkers indicate disease pathogenesis, which provides opportunities to select treatment, including treatment regimens intended to identify responsive candidates and overcome resistance mechanisms.

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, Methods and compositions for determining cancer and subtypes, including breast cancer are described and specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at identifying candidates for responsiveness and overcoming resistance mechanisms.

The invention relates to a paulownia fortunei PfD27 gene and construction and application of an expression vector of the paulownia fortunei PfD27 gene. The paulownia fortunei strigolactones are screened from a paulownia fortunei genome through a bioinformatics method to synthesize related beta-carotene isomerase DWARF27 (D27) gene. The nucleotide sequence of the PfD27 gene is as shown in SEQ ID NO. 1, and the amino acid sequence of the protein encoded by the PfD27 gene is as shown in SEQ ID NO. 2. According to the invention, paulownia fortunei PfD27 expression vectors such as pSAK277-PfD27-eGFP, pET-28a (+)-SUMO-PfD27, pCAMBIA3301-PfD27 and the like are constructed, subcellular localization analysis of the paulownia fortunei PfD27 protein, prokaryotic expression and purification of the PfD27 protein and research on the influence of PfD27 gene overexpression on tomato branches are respectively carried out, the function of the paulownia fortunei PfD27 gene is explained in the aspects of strigolactones biosynthesis and plant branch regulation and control, and the application of the paulownia fortunei PfD27 gene is developed. Reference is provided for subsequently revealing the relationship between the paulownia fortunei arbuscular disease pathogenesis and strigolactones hormone, and a molecular basis is provided for cultivation of new varieties of ideal paulownia plant types.